» Articles » PMID: 12377770

Rac1-MKK3-p38-MAPKAPK2 Pathway Promotes Urokinase Plasminogen Activator MRNA Stability in Invasive Breast Cancer Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2002 Oct 16
PMID 12377770
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

We reported previously that down-regulating or functionally blocking alphav integrins inhibits endogenous p38 mitogen-activated protein kinase (MAPK) activity and urokinase plasminogen activator (uPA) expression in invasive MDA-MB-231 breast cancer cells whereas engaging alphav integrins with vitronectin activates p38 MAPK and up-regulates uPA expression (Chen, J., Baskerville, C., Han, Q., Pan, Z., and Huang, S. (2001) J. Biol. Chem. 276, 47901-47905). Currently, it is not clear what upstream and downstream signaling molecules of p38 MAPK mediate alphav integrin-mediated uPA up-regulation. In the present study, we found that alphav integrin ligation activated small GTPase Rac1 preferentially, and dominant negative Rac1 inhibited alphav integrin-mediated p38 MAPK activation. Using constitutively active MAPK kinases, we found that both constitutively active MKK3 and MKK6 mutants were able to activate p38 MAPK and up-regulate uPA expression, but only dominant negative MKK3 blocked alphav integrin-mediated p38 MAPK activation and uPA up-regulation. These results suggest that MKK3, rather than MKK6, mediates alphav integrin-induced p38 MAPK activation. Among the potential downstream effectors of p38 MAPK, we found that only MAPK-activated protein kinase 2 affects alphav integrin-mediated uPA up-regulation significantly. Finally, using beta-globin reporter gene constructs containing uPA mRNA 3'-untranslated region (UTR) and adenosine/uridine-rich elements-deleted 3'-UTR, we demonstrated that p38 MAPK/MAPK-activated protein kinase 2 signaling pathway regulated uPA mRNA stability through a mechanism involving the adenosine/uridine-rich elements sequence in 3'-UTR of uPA mRNA.

Citing Articles

Roles for epithelial integrin α3β1 in regulation of the microenvironment during normal and pathological tissue remodeling.

Miskin R, DiPersio C Am J Physiol Cell Physiol. 2024; 326(5):C1308-C1319.

PMID: 38497112 PMC: 11371326. DOI: 10.1152/ajpcell.00128.2024.


Review and Application of Integrin Alpha v Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma.

Lian Y, Zeng S, Wen S, Zhao X, Fang C, Zeng N Technol Cancer Res Treat. 2023; 22:15330338231189399.

PMID: 37525872 PMC: 10395192. DOI: 10.1177/15330338231189399.


P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma.

Banik I, Ghosh A, Beebe E, Burja B, Frank Bertoncelj M, Dooley C Cancers (Basel). 2023; 15(3).

PMID: 36765834 PMC: 9913513. DOI: 10.3390/cancers15030877.


Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.

Zhai B, Tian H, Sun J, Zou J, Zhang X, Cheng J J Transl Med. 2022; 20(1):135.

PMID: 35303878 PMC: 8932206. DOI: 10.1186/s12967-022-03329-3.


Articular Chondrocyte Phenotype Regulation through the Cytoskeleton and the Signaling Processes That Originate from or Converge on the Cytoskeleton: Towards a Novel Understanding of the Intersection between Actin Dynamics and Chondrogenic Function.

Lauer J, Selig M, Hart M, Kurz B, Rolauffs B Int J Mol Sci. 2021; 22(6).

PMID: 33807043 PMC: 8004672. DOI: 10.3390/ijms22063279.